术前免疫检查点抑制剂治疗与高危手术后心肺不稳定及器官损伤的关联
本研究为单中心回顾性队列研究,纳入7674例术后入住ICU的癌症患者,其中247例在术前6个月内使用过一种或多种FDA批准的免疫检查点抑制剂(ICI)。经倾向性评分匹配后,197例ICI暴露者与777例非暴露者进行比较。主要复合终点( prolonged pressor or oxygen dependence、肾损伤或心肌损伤)在ICI暴露组为70/197(35.5%),非暴露组为251/777(32.3%),条件logistic回归显示无差异(OR 1.12,95%CI 0.80-1.58)。次要终点中,升压药依赖时间延长风险在ICI暴露组显著更高(OR 1.64,95%CI 1.01-2.67),而氧依赖、肾损伤和心肌损伤风险无显著差异;两组存活出院时间无差异(p=0.62)。结论认为术前6个月内ICI暴露与复合终点无关,但心脏不稳定和损伤的次要终点关联值得未来研究。
要点
- 术后ICU癌症患者中,术前6个月内ICI暴露者主要复合终点发生率35.5%(70/197),非暴露者32.3%(251/777),OR 1.12(95%CI 0.80-1.58),无显著差异。
- ICI暴露组升压药依赖时间延长的风险显著高于非暴露组(OR 1.64,95%CI 1.01-2.67)。
- 氧依赖(OR 1.13,95%CI 0.75-1.73)、肾损伤(OR 1.15,95%CI 0.77-1.71)、心肌损伤(OR 1.76,95%CI 1.00-3.10)风险均无显著差异。
- 两组存活出院时间无差异(p=0.62)。
- 作者认为,心脏不稳定和损伤的次要终点潜在关联值得未来研究。
适用人群与场景
- 癌症患者,术后入住ICU,纳入7674例;其中247例在术前6个月内使用过一种或多种FDA批准的ICI。
- 经倾向性评分匹配后分析197例ICI暴露者与777例非暴露者。
- 场景为高危手术后ICU监护阶段。
诊断标准与关键阈值
- 主要暴露:术前6个月内使用FDA批准的ICI。
- 主要复合终点:术后并发症复合终点,包括升压药或氧依赖时间延长、肾损伤或心肌损伤。
研究设计与关键结果
- 单中心回顾性队列研究,7674例癌症术后ICU患者,247例术前6个月内ICI暴露;倾向性评分匹配后197例暴露者与777例非暴露者。
- 主要复合终点:ICI暴露组70/197(35.5%) vs 非暴露组251/777(32.3%),OR 1.12(95%CI 0.80-1.58),无显著差异。
- 次要终点升压药依赖时间延长:ICI暴露组风险显著更高,OR 1.64(95%CI 1.01-2.67)。
- 次要终点氧依赖:OR 1.13(95%CI 0.75-1.73),无显著差异。
- 次要终点肾损伤:OR 1.15(95%CI 0.77-1.71),无显著差异。
- 次要终点心肌损伤:OR 1.76(95%CI 1.00-3.10),无显著差异。
- 存活出院时间:两组无差异(p=0.62)。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,癌症患者高危手术前6个月内ICI暴露与术后心肺不稳定或器官损伤复合终点无关。
- 作者认为,心脏不稳定和损伤的次要终点潜在关联值得未来研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the relationship between prior exposure to immune checkpoint inhibitors (ICIs) and the risk of postoperative complications in cancer patients.
DESIGN: Single-center retrospective cohort study.
INTERVENTIONS: The main exposure was treatment with an FDA-approved ICI within 6 months before surgery.
MEASUREMENTS AND MAIN RESULTS: Exposure to ICIs and covariates was determined from the electronic health record. The primary outcome was a composite of postoperative complications, including prolonged pressor or oxygen dependence, kidney injury, or myocardial injury. Secondary outcomes included each subcomponent of the primary outcome. Of 7674 subjects with cancer admitted to the ICU after surgery, 247 were exposed to one or more ICIs in the 6 months before surgery. After propensity score matching, 197 ICI-exposed subjects were matched to 777 nonexposed. The composite outcome occurred in 70 of 197 (35.5%) ICI-exposed subjects and 251 of 777 (32.3%) nonexposed. There was no difference between exposed and nonexposed groups in the primary composite outcome (odds ratio [OR], 1.12; 95% CI, 0.80-1.58) by conditional logistic regression. Risk of the secondary outcome of prolonged pressor dependence was significantly higher in ICI-exposed subjects (OR, 1.64; 95% CI, 1.01-2.67). Risks of oxygen dependence (OR, 1.13; 95% CI, 0.75-1.73), kidney injury (OR, 1.15; 95% CI, 0.77-1.71), and myocardial injury (OR, 1.76; 95% CI, 1.00-3.10) were not significantly different. There was no difference between groups in the time to hospital discharge alive (p = 0.62).
CONCLUSIONS: Exposure to ICIs within 6 months before high-risk surgery was not associated with the composite outcome of cardiopulmonary instability or organ injury in patients with cancer. The potential for an association with the secondary outcomes of cardiac instability and injury is worthy of future study.
参考来源
- Tang YH, Bergmann J, Vaidya D, et al. Association of Preoperative Immune Checkpoint Inhibitor Therapy With Cardiopulmonary Instability and Organ Injury After High-Risk Surgery. Crit Care Explor. 2024. PMID: 38562380. doi:10.1097/CCE.0000000000001068
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。